NATICK, Mass., July 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that William E. Young has been appointed Vice President of Quality Assurance and Reliability for the Company’s Cardiac Rhythm Management (CRM) Group. He will be responsible for all quality assurance and reliability functions for the CRM Group, including product performance reporting. Young will report to Fred Colen, Executive Vice President, Operations and Technology -- CRM and Chief Technology Officer at Boston Scientific. He will be based at the Company’s St. Paul, Minnesota facility, headquarters of the CRM Group.
“Bill brings an impressive depth of experience in quality assurance to our management team,” said Colen. “Combined with his leadership skills, operations background and knowledge of the healthcare industry, Bill will be a key contributor to our CRM team.”
Prior to joining Boston Scientific, Young served as Vice President of Quality Assurance and Regulatory Affairs for Smiths Medical in London. While in this position, he was responsible for all quality assurance and regulatory affairs activities for the company’s $1.3 billion medical device division. He also successfully implemented standardized metrics for measuring and trending quality indicators at all Smiths manufacturing facilities, established a quality policy and defined an integration strategy for all acquired businesses. Before Smiths Medical, Young was Vice President of Quality Management for the Medication Delivery Division of Baxter Healthcare Corporation in Deerfield, IL.
He is currently a member of the U.S. Food and Drug Administration’s Industrial Sterilization Training Cadre, co-chair of the Association for the Advancement of Medical Instrumentation Sterilization Standards Committee and chairman of the International Standards Organization (ISO) Sterilization Standards Committee. He holds an MBA degree from Northern Illinois University and a Bachelor of Science degree in Mechanical Engineering from the University of Illinois.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific’s overall business strategy, and other factors described in Boston Scientific’s filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or PaulDonovan, Media Relations, +1-508-650-8541, both of Boston ScientificCorporation
Web site: http://www.bostonscientific.com/
